• 1. Synthesis of 18F-difluoromethylarenes using aryl boronic acids, ethyl bromofluoroacetate and [18F]fluoride
  Jeroen B. I. Sap,Thomas C. Wilson,Choon Wee Kee,Natan J.?W. Straathof,Christopher W. am Ende,Paramita Mukherjee,Lei Zhang,Christophe Genicot,Véronique Gouverneur Chem. Sci. 2019 10 3237
• 2. Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors
  Sabrina Touchet,Fran?ois Carreaux,Bertrand Carboni,Alexandre Bouillon,Jean-Luc Boucher Chem. Soc. Rev. 2011 40 3895
• 3. Late-stage difluoromethylation: concepts, developments and perspective
  Jeroen B. I. Sap,Claudio F. Meyer,Natan J. W. Straathof,Ndidi Iwumene,Christopher W. am Ende,Andrés A. Trabanco,Véronique Gouverneur Chem. Soc. Rev. 2021 50 8214
• 4. 17O NMR studies of boronic acids and their derivatives
  B?a?ej Gierczyk,Marcin Ka?mierczak,Grzegorz Schroeder,Andrzej Sporzyński New J. Chem. 2013 37 1056
• 5. Hot off the press
  Robert A. Hill,Marie Claire Parker Nat. Prod. Rep. 2000 17 4-iii

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Boronic acid derivatives Boronic acids
• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of Ethylboronic Acid (CAS: 4433-63-0) in Chemical Biology and Pharmaceutical Research

Ethylboronic acid (CAS: 4433-63-0) has emerged as a versatile compound in chemical biology and pharmaceutical research due to its unique reactivity and applications in drug discovery, catalysis, and materials science. Recent studies have highlighted its role as a key intermediate in the synthesis of boron-containing compounds, which are increasingly important in medicinal chemistry. This research brief consolidates the latest findings on ethylboronic acid, focusing on its synthesis, mechanisms of action, and potential therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of ethylboronic acid derivatives as potent inhibitors of bacterial β-lactamases, enzymes responsible for antibiotic resistance. The research team utilized structure-activity relationship (SAR) analysis to optimize the boronic acid moiety, achieving significant improvements in inhibitory activity against clinically relevant pathogens. These findings underscore the potential of ethylboronic acid as a scaffold for developing next-generation antibiotics.

In the field of cancer therapeutics, ethylboronic acid has been investigated for its role in boron neutron capture therapy (BNCT). A recent preclinical study published in Bioorganic & Medicinal Chemistry Letters reported the development of tumor-targeting ethylboronic acid conjugates that selectively accumulate in cancer cells. The study demonstrated enhanced boron delivery efficiency and improved therapeutic outcomes in murine models, paving the way for future clinical trials.

Advances in synthetic methodology have also expanded the utility of ethylboronic acid. A 2024 paper in Organic Letters described a novel palladium-catalyzed cross-coupling reaction using ethylboronic acid as a nucleophilic partner, enabling the efficient construction of complex molecular architectures. This methodology has been applied to the synthesis of bioactive natural products and pharmaceutical intermediates, demonstrating the compound's versatility in organic synthesis.

From a mechanistic perspective, computational studies have provided new insights into the interactions of ethylboronic acid with biological targets. Molecular dynamics simulations published in Journal of Chemical Information and Modeling revealed the importance of boronic acid-diol interactions in enzyme inhibition, offering a rational basis for the design of more effective inhibitors. These computational approaches complement experimental findings and accelerate drug discovery efforts.

Looking forward, researchers are exploring the potential of ethylboronic acid in emerging areas such as proteolysis-targeting chimeras (PROTACs) and covalent inhibitors. Preliminary results suggest that the boronic acid moiety can enhance target engagement and improve pharmacokinetic properties. As the field continues to evolve, ethylboronic acid (CAS: 4433-63-0) remains a valuable tool for chemical biologists and medicinal chemists working at the interface of chemistry and biology.

• 80041-89-0((propan-2-yl)boronic acid)
• 2241867-57-0((ethyl-d5)boronic acid)
• 237401-34-2
• 17745-45-8(Propylboronic acid)
• 8002-41-3(Isopropylboronic acid)
• 2241867-55-8((propan-2-yl-d7)boronic acid)
• 2241867-56-9((propyl-d7)boronic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)